Olanzapine dosing study for schizophrenia
Part of Mental health clinical trials.
This trial tests a slower, lower-dose schedule of the drug olanzapine for people with schizophrenia. It aims to see if a gentler start is safer and works as well, especially for those who may need less medication due to other health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with schizophrenia for more than 1 year.
- Your doctor thinks a lower starting dose or slower increase of olanzapine would be better for you.
- You do not have other conditions like schizoaffective disorder, bipolar disorder, or major depression.
- You have not been hospitalized for worsening schizophrenia in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination tablet (olanzapine-samidorphan) for adults with schizophrenia. It aims to see if it helps control symptoms while potentially reducing weight gain, which can be a side effect of some schizophrenia medicines.
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
This study looks at how well patients with bipolar disorder do while taking the medication olanzapine. You will continue your regular treatment, and answer questions about your experience.
This study tests whether gradually reducing the dose of antipsychotic medication is as safe and effective as staying on the current dose for people with stable schizophrenia spectrum disorder. It aims to personalize treatment to find the lowest effective dose for each person.
This trial looks at whether taking an antipsychotic every other day can keep symptoms controlled in adults with schizophrenia or another psychotic disorder. It may help some people avoid daily dosing, but it requires specific medication stability and screening checks.
This trial tests whether a lower dose of olanzapine (2.5 mg) works as well as the usual dose (5 mg) for preventing nausea and vomiting caused by high-dose melphalan chemotherapy. It is for people receiving their own stem cell transplant.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.